Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) Receives $20.89 Consensus Target Price from Analysts

Y-mAbs Therapeutics, Inc. (NASDAQ:YMAB) has received an average recommendation of “Buy” from the ten ratings firms that are covering the company, MarketBeat Ratings reports. One equities research analyst has rated the stock with a sell rating, seven have given a buy rating and two have issued a strong buy rating on the company. The average 12-month price objective among analysts that have issued a report on the stock in the last year is $20.89.

Several research analysts have recently issued reports on the stock. Oppenheimer began coverage on shares of Y-mAbs Therapeutics in a research note on Monday, November 18th. They issued an “outperform” rating and a $23.00 target price on the stock. HC Wainwright reaffirmed a “buy” rating and issued a $22.00 price objective on shares of Y-mAbs Therapeutics in a research note on Monday, January 13th. Brookline Capital Management began coverage on shares of Y-mAbs Therapeutics in a research note on Thursday, December 5th. They set a “buy” rating and a $17.00 price target on the stock. Finally, Wedbush reissued an “outperform” rating and issued a $23.00 price objective on shares of Y-mAbs Therapeutics in a research report on Friday, January 10th.

Y-mAbs Therapeutics Stock Up 2.0 %

NASDAQ:YMAB opened at $6.15 on Tuesday. Y-mAbs Therapeutics has a 12 month low of $5.71 and a 12 month high of $20.90. The company has a 50-day moving average price of $7.67 and a 200-day moving average price of $11.26.

Y-mAbs Therapeutics (NASDAQ:YMAB) last issued its quarterly earnings results on Friday, November 8th. The company reported ($0.16) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.14) by ($0.02). Y-mAbs Therapeutics had a negative net margin of 28.22% and a negative return on equity of 24.61%. The business had revenue of $18.46 million for the quarter, compared to analysts’ expectations of $23.38 million. During the same period last year, the business earned ($0.18) earnings per share. Research analysts forecast that Y-mAbs Therapeutics will post -0.64 earnings per share for the current year.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. State Street Corp lifted its holdings in Y-mAbs Therapeutics by 50.4% during the 3rd quarter. State Street Corp now owns 1,209,781 shares of the company’s stock worth $15,909,000 after buying an additional 405,169 shares in the last quarter. Caligan Partners LP grew its stake in shares of Y-mAbs Therapeutics by 105.3% in the 3rd quarter. Caligan Partners LP now owns 1,195,253 shares of the company’s stock valued at $15,718,000 after purchasing an additional 613,175 shares during the last quarter. Geode Capital Management LLC increased its stake in shares of Y-mAbs Therapeutics by 6.2% during the third quarter. Geode Capital Management LLC now owns 813,489 shares of the company’s stock worth $10,699,000 after acquiring an additional 47,846 shares during the period. Dimensional Fund Advisors LP raised its position in Y-mAbs Therapeutics by 15.7% in the second quarter. Dimensional Fund Advisors LP now owns 484,431 shares of the company’s stock worth $5,853,000 after acquiring an additional 65,732 shares in the last quarter. Finally, Millennium Management LLC boosted its stake in shares of Y-mAbs Therapeutics by 23.8% during the 2nd quarter. Millennium Management LLC now owns 349,784 shares of the company’s stock worth $4,225,000 after acquiring an additional 67,233 shares in the last quarter. Hedge funds and other institutional investors own 70.85% of the company’s stock.

About Y-mAbs Therapeutics

Y-mAbs Therapeutics, Inc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of antibody based therapeutic products for the treatment of cancer in the United States and internationally. It offers DANYELZA, a monoclonal antibody in combination with granulocyte-macrophage colony-stimulating factor for the treatment of pediatric patients with relapsed or refractory high-risk neuroblastoma in the bone or bone marrow.